Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: May 15, 2025
Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40 patients; enrollment expected to close in June 2025
Read more at globenewswire.com
